The future of chronic lymphocytic leukemia treatment
Over the past ten years the treatment of CLL has changed greatly with the abandonment of conventional immunochemotherapy and the development of targeted drugs, including Bruton‘s tyrosine kinase inhibitors (BTKi) and BCL2 inhibitors. This has increased the need to optimize their use in order to ensure the greatest possible effectiveness and a personalized approach to the treatment. Although the new treatment options have significantly improved clinical outcomes, high-risk patients do not respond optimally to treatment. Furthermore, resistance mechanisms have emerged, especially with continuous drug use, which lead to the progression of CLL or Richter‘s transformation. Thus, there is a clinical need to identify new therapeutic strategies. CLL remains an incurable disease, and the molecular mechanisms underlying the progression of the disease are still insufficiently known. The best combinations and order of administration of targeted drugs with MRD guidance, as well as the integration of new drugs will be derived from clinical trials, and the results will need to be integrated into clinical practice.
Key words:
BCL2 inhibitors; BTK inhibitors; CLL; MRD; new drugs; personalized treatment
OGLASI
